» Articles » PMID: 22131893

Pros and Cons of Medical Management of Ulcerative Colitis

Overview
Date 2011 Dec 2
PMID 22131893
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Ulcerative colitis (UC) is a chronic inflammatory disease characterized by diffuse mucosal inflammation limited to the colon and rectum. Although a complete medical cure may not be possible, UC can be treated with medications that induce and maintain remission. The medical management of this disease continues to evolve with a goal to avoid colectomy and ultimately alter the natural history of UC. Emergence of antitumor necrosis factor-α (TNF-α) agents has expanded the medical armamentarium. 5-Aminosalicylates continue to be used in mild to moderate UC and corticosteroids are mainly used for induction of remission with immunomodulators (6-mercaptopurine/azathiopurine/methotrexate) being applied as steroid-sparing agents for maintenance therapy. Infliximab has been approved by the U.S. Food and Drug Administration and used in the treatment of moderate to severe UC; nevertheless, its use may be associated with significant adverse effects and have a negative impact on the postoperative course should the patients undergo restorative proctocolectomy. In addition, there is always a concern about patients' compliance to medical therapy, cost of medications, and risk for UC-associated dysplasia. The authors discuss the pros and cons of medications used in the treatment of UC.

Citing Articles

How the Western Diet Thwarts the Epigenetic Efforts of Gut Microbes in Ulcerative Colitis and Its Association with Colorectal Cancer.

Majumder A, Bano S Biomolecules. 2024; 14(6).

PMID: 38927037 PMC: 11201633. DOI: 10.3390/biom14060633.


Efficacy and safety of fecal microbiota transplantation for the induction of remission in active ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.

Wei Z, Dong H, Ren Y, Jiang B Ann Transl Med. 2022; 10(14):802.

PMID: 35965832 PMC: 9372650. DOI: 10.21037/atm-22-3236.


Carbocisteine as a Modulator of Nrf2/HO-1 and NFκB Interplay in Rats: New Inspiration for the Revival of an Old Drug for Treating Ulcerative Colitis.

Abdelhamid A, Youssef M, Cavalu S, Mostafa-Hedeab G, Youssef A, Elazab S Front Pharmacol. 2022; 13:887233.

PMID: 35754464 PMC: 9214041. DOI: 10.3389/fphar.2022.887233.


The effect of Hericium erinaceum on the prevention of chemically induced experimental colitis in rats.

Durmus A, Durmus I, Bender O, Karatepe O Korean J Intern Med. 2020; 36(Suppl 1):S44-S52.

PMID: 32550720 PMC: 8009150. DOI: 10.3904/kjim.2019.050.


The Bisindole Alkaloid Caulerpin, from Seaweeds of the Genus , Attenuated Colon Damage in Murine Colitis Model.

Lucena A, Souza C, Jales J, Guedes P, de Miranda G, de Moura A Mar Drugs. 2018; 16(9).

PMID: 30205459 PMC: 6163434. DOI: 10.3390/md16090318.

References
1.
Lofberg R, Danielsson A, Suhr O, Nilsson A, Schioler R, Nyberg A . Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology. 1996; 110(6):1713-8. DOI: 10.1053/gast.1996.v110.pm8964395. View

2.
Oliva-Hemker M, Abadom V, Cuffari C, Thompson R . Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2007; 44(2):180-4. DOI: 10.1097/MPG.0b013e31802b320e. View

3.
Selvasekar C, Cima R, Larson D, Dozois E, Harrington J, Harmsen W . Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007; 204(5):956-62. DOI: 10.1016/j.jamcollsurg.2006.12.044. View

4.
Sutherland L, MacDonald J . Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; (2):CD000543. DOI: 10.1002/14651858.CD000543.pub2. View

5.
Thirlby R, Sobrino M, Randall J . The long-term benefit of surgery on health-related quality of life in patients with inflammatory bowel disease. Arch Surg. 2001; 136(5):521-7. DOI: 10.1001/archsurg.136.5.521. View